April 1, 2018 (Vol. 38, No. 7)
Longeveron-Grown Stem Cells Advance on Aging Frailty and Related Disabilities
The stem cell industry took some nasty blows in the early 2000s, when the morality of using embryonic stem cells was questioned and all but a few lines of those cells were excluded from federal research grants. Stem cell experts left the United States for laboratories in Singapore and elsewhere.
In the void that remained, determined stem cell researchers found a way forward: adult stem cells. These cells are found throughout the bodyin bone marrow, hair follicles, and other tissuesand they are multipotent, which means they retain the ability to differentiate into some or all of the specialized cell types of the tissue or organ in which they are embedded. Although adult stem cells lack the pluripotency of embryonic stem cells, they can be reprogrammed to become cells of a specific cell type or induced pluripotent stem cells.
The reprogramming technology developed by stem cell researchers is beginning to bear fruit. Although it is not the low-hanging fruit envisaged at the dawn of stem cell science, it is worth the reach. Applications are being developed for basic research, drug testing, and cell-based therapeutics. This last application area, which promises to generate replacement cells and tissues, may be the most important. It is being explored by several companies that hope to manufacture adult stem cells and thereby reinvigorate regenerative medicine. One of companies is Longeveron. By producing allogeneic mesenchymal stem cells (MSCS) from adult human bone marrow MSCs, Longeveron intends to ameliorate diseases and disabilities associated with aging.
Frailty and Diseases of Aging
Im a cardiologist, but Ive long been interested in medical diseases of aging, begins Joshua M. Hare, M.D., co-founder and CSO, Longeveron. Heart disease primarily affects older people, and age is a huge risk factor.
Frailty associated with aging is an underappreciated problem, he continues, adding that it affects approximately 12% of all people age 65 or older. Besides becoming familiar with the statistics of aging frailty, Dr. Hare saw it in his practice.
Dr. Hare has been thinking about the causes of frailty among otherwise healthy people for at least 20 years. Frailty affects so many people of advanced age, yet almost nothing is being done for this group, he notes. It represents a huge challenge.
Aging, he explains, affects all of our organs. Older hearts dont work as well as younger hearts, all other things being equal. Therefore, we hypothesized that the decline in function was related to the depletion of normal adult stem cells in the body. Then we found a way to replete them. For us, it was a Eureka! moment.
A Biotech Founded to Bring MSCs to Market
Dr. Hare says that he co-founded Longeveron in 2014 for the express purpose of bringing the benefits of MSC technology to a broad population. Universities arent set up to take a new therapeutic through the regulatory steps to bring a drug to market, he points out. Rather than hope a biotech company would be interested in acquiring the research, he took matters into his own hands.
Now Longeveron manufactures MSCs in a proprietary process that the company exclusively licensed from the University of Miami. The cells are introduced into the body intravenously.
The decision to form a company was based on clinical trial results, he says. He and his team had recently conducted and published the results of a 45-patient allogeneiC human mesenchymal stem cells in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study. Not only were the patients showing positive responses, they were doing very, very well, Dr. Hare recalls. This was exciting because there were no successful medical therapies whatsoever for this condition. Those trial results were validated by favorable responses from the geriatric medicine community.
One very public sign of approval came in the form of an editorial in the October 2017 issue of The Journals of Gerontology: Series A. The editorials authors called MSC translation a promising and innovative approach for the treatment of frailty in older humans.
The same issue of the journal also published an article summarizing the results of a small, 30-person study. According to this article, treated patients showed remarkable improvements in physical performance measures and inflammatory biomarkers, both of which characterize frailty syndrome. It concluded that larger trials were warranted.
A Check on Inflammation
The use of MSCs to treat aging is a new and exciting component of biotech, Dr. Hare points out. The theory holds that transplanted MSCs can reduce the chronic inflammation associated with aging and aging-related disease, and thereby improve functional capacity and quality of life. At another level, MSCs have the potential to ameliorate diseases and conditions of aging and, perhaps, even increase longevity.
Despite this potential, Dr. Hare cautions against unrealistic expectations: There are quite a few startups, but few major companies are far along in terms of developing or commercializing this type of therapeutic.
Slightly more than three years old, Longeveron has one therapeutic in Phase IIb clinical trials. Additional trials are open. Some are focused on aging frailty; others are evaluating the cells as a way to treat Alzheimers disease.
Longeveron recently indicated that it had completed enrollment for the second cohort of a Phase I/II trial to test the safety and efficacy of a mesenchymal stem cell therapy for improving influenza vaccine response in patients with aging frailty. The company expects data in 2018.
The Competitive Landscape
Designed from MSCs extracted from bone marrow, the therapeutic product is allogenic. It can be made in large quantities and will be available off-the-shelf. Currently, says Dr. Hare, there are no MSCs on the United States market, although one MSC therapy has been approved. Also, two or three companies are pressing ahead with the development of MSC therapies.
According to Dr. Hare, Longeverons MSCs are unique in two respects: the way they are produced, and the way they are characterized. The specifics of manufacturing and the cells characterization features, however, are confidential. They are trade secrets, Dr. Hare insists.
In a recent interview, Dr. Hare was not only reticent about Longeverons technology, he was also vague about the specific challenges the company has weatheredbut not because all these challenges are particulalry sensitive. He was hurrying to help a patient. He did mention, however, challenges pertaining to the specific (and confidential) methods used to turn a cell into a drug, and the FDA guidances for those methods. The next step for the young company, he said, is to begin negotiations with the FDA to design Phase III trials.
In January, Longeveron won a research grant from the National Institutes of Health (NIH) to develop therapeutics to combat metabolic syndrome. The $1.15 million grant is part of the NIH Fast Track program for small businesses. Earlier, the company received clinical trials funding from Alzheimers Association and Marylands Technology Development Corporation (TEDCO).
Dr. Hare attributes Longeverons success to date to a capable team. Dr. Hare himself is founding director of the University of Miamis Interdisciplinary Stem Cell Institute (ISCI). The scientific advisory board includes thought leaders in geriatrics and cardiology from leading institutions in the United States and Japan. Management team members have histories in academia and corporate operations. None, however, has taken a drug to market.
In the end, a lack of commercialization experience may not matter. Longeveron, recognizing its strengths, plans to partner for that phase of its journey.
A Booming Market
If future trials are as successful as Dr. Hare hopes, Longeverons new therapy will be firmly on the path to commercialization. Given the global population of aging baby boomers, he envisions a broad market for the therapy.
People came to us in droves for the clinical trials, Dr. Hare reports. Having the signs and symptoms of frailty troubles people. They have a palpable sense of becoming disabled simply because they are aging. They want to improve their quality of life.
Regenerative therapies already are gaining regulatory approval for many indications. And, while aging has been largely ignored, it is unlikely to be ignored much longer.
If Longeverons approach is eventually commercialized, in the not-too-distant future, any geriatrician or general practice physician should be able to administer Longeverons MSCs to roll back frailty and possibly reduce other deficits in functional capacity related to aging, such as Alzheimers disease and metabolic syndrome.
Location: Life Science & Technology Park' 1951 NW 7th Avenue, Suite 520, Miami, FL 33136
Phone: (305) 909-0840
Principal: Joshua M. Hare, M.D., Co-Founder and CSO
Number of Employees: 18
Focus: Longeveron, a clinical stage company, produces mesenchymal stem cells to alleviate frailty and other conditions associated with aging.
Originally posted here:
Adult Stem Cells Show Anti-Aging Potential - genengnews.com
- Brenner and Rector's The Kidney, 2-Volume Set. Edition No. 11 - ResearchAndMarkets.com - Associated Press - December 6th, 2019
- Stem Cells Market to a Revenue Opportunity of US$270.5 bn During the Period from 2025 - News Description - December 6th, 2019
- Stem cell Therapy Market 2019-2027| Business Scope and Investment Analysis By MEDIPOST, PHARMICELL Co., Ltd, Holostem Terapie Avanzate Srl, Mesoblast... - December 6th, 2019
- Cutting Through the Headlines: Are Scientists Really Growing Sentient "Mini-brains"? - Technology Networks - December 6th, 2019
- Year in Review: Respiratory Infection - MedPage Today - December 6th, 2019
- Whats Happening: IDF Shabbat of Heroes, Sephardic Papers - Jewish Journal - December 5th, 2019
- Global Stem Cells Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Breaking News Updates - December 5th, 2019
- Marine Coatings Market is Anticipated to Register a Value of XX Million by the end of 2017 - 2025 - Markets Gazette 24 - December 5th, 2019
- Stem Cell Market 2019 | What Will Be the Market Size and the Growth Rate Analysis by 2026? - Hitz Dairies - December 3rd, 2019
- Stem Cells Market is Expected to Register a Healthy CAGR of 13.8% During the Period from 2017 to 2025 - Statsflash - December 3rd, 2019
- BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND - BioSpace - November 28th, 2019
- Inside the Beltway: Abortion, immigration among forbidden topics at Thanksgiving table - Washington Times - November 28th, 2019
- Canine Stem Cell Therapy Market Value Projected to Expand by 2026 - The Hilltop Monitor - November 28th, 2019
- Global Stem Cells Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Industry News Info - November 28th, 2019
- Stem Cell Banking Market Size, Share, Growth, Future Prospects, Competitive Analysis and Forecast To 2026 - Med News Ledger - November 28th, 2019
- Lulu and Nana are the result of a defiant experiment in human gene modification - The Irish Times - November 28th, 2019
- Types of Adult Stem Cells - Stem Cell Institute - November 26th, 2019
- Adult Leukemia: What You Need to Know - Dana-Farber Cancer Institute - November 26th, 2019
- Hatching disease in a dish: The new frontier in drug testing - Maclean's - November 26th, 2019
- Bedfordshire Police officer reunited with woman whose life he saved through stem cell donation - Bedford Today - November 26th, 2019
- BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND - GlobeNewswire - November 26th, 2019
- Bedfordshire Police officer reunited with stem cell recipient - Cranfield and Marston Vale Chronicle - November 26th, 2019
- Keeping cells alive | Interviews - The Naked Scientists - November 26th, 2019
- Dana-Farber joins with leading Boston teaching hospitals and universities - Mirage News - November 26th, 2019
- Applying AI and CRISPR to stem cells to improve regenerative medicine - FierceBiotech - November 20th, 2019
- Decoding the building blocks of life: bit bio races toward a sustainable source of human cells - Proactive Investors UK - November 20th, 2019
- 1st SCD Trial Patient Shows CTX001 Gene Editing to be Safe, Effective - Sickle Cell Anemia News - November 20th, 2019
- CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib - BioSpace - November 20th, 2019
- Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology - Arizona Daily Star - November 20th, 2019
- Maltese abroad: the best-selling author with roots in Gozo - Times of Malta - November 20th, 2019
- Early Results Are Positive for Experimental CRISPR Therapies - The Scientist - November 19th, 2019
- CHMP recommends EMA approval of polatuzumab vedotin for the treatment of adult patients with R/R DLBCL - Lymphoma Hub - November 19th, 2019
- CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib - PRNewswire - November 19th, 2019
- Redding woman donates bone marrow, saves life of a father - FOX61 Hartford - November 16th, 2019
- Maxim Group Maintains Their Buy Rating on Brainstorm Cell Therapeutics (BCLI) - Smarter Analyst - November 16th, 2019
- How 3D Printing Is Turning Each And Every Industry On Its Head - SafeHaven.com - November 16th, 2019
- BIORESTORATIVE THERAPIES, INC. (OTCMKTS:BRTX) Files An 8-K Submission of Matters to a Vote of Security Holders - Market Exclusive - November 16th, 2019
- Global Cell Expansion Market 2019 is predicted to reach an excellent valuation of by 2024 - Galus Australis - November 16th, 2019
- Stem Cell Assay Market is Growing Massively in Upcoming Year with Top Key Players like GE Healthcare, Thermo Fisher Scientific Inc., Merck KGaA, Cell... - November 15th, 2019
- Bone marrow transplant: What it is, uses, risks, and recovery - Medical News Today - November 15th, 2019
- The Demand of Mesenchymal Stem Cells Market Research Report 2019 Future Growth, Demand, Application, Trends, Vendor Landscape, Industry Insight,... - November 15th, 2019
- BrainStorm Cell Therapeutics Announces Research Grant Award From the National Multiple Sclerosis Society - Yahoo Finance - November 14th, 2019
- BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate Update - GlobeNewswire - November 14th, 2019
- BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting - Yahoo Finance - November 14th, 2019
- INDIA Indian doctor: Medical innovation should not try to replace the Creator - AsiaNews - November 14th, 2019
- iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations at 61st American Society of Hematology Annual Meeting - Send2Press Newswire - November 14th, 2019
- Contrasting BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) - DFS Caller - November 14th, 2019
- Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell... - November 12th, 2019
- Army veteran to save woman with blood cancer through stem cell donation - Stoke-on-Trent Live - November 12th, 2019
- Financial Contrast: BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) - DFS Caller - November 12th, 2019
- Autolus Therapeutics Plc (AUTL) Q3 2019 Earnings Call Transcript - The Motley Fool - November 9th, 2019
- Stem Cell Therapy Market Trends, Secondary Research With Geron Corporation, Vericel Corporation, Pluristem Therapeutics, Cytori Therapeutics, Fate... - October 29th, 2019
- Huntington's Marked by Inflammation and Changes in Brain's Striatum Before Symptoms, Study Finds - Huntington's Disease News - October 29th, 2019
- In 2030, Our Protein Will Come From a Laband We'll All Be Better Off For It - Singularity Hub - October 28th, 2019
- NASA plans to cut cost of space exploration by commercializing low-earth orbit - Digital Trends - October 27th, 2019
- BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference - BioSpace - October 27th, 2019
- Artificial Early Mouse Embryos Created In The Lab Using Stems Cells Rather Than Sperm Or Eggs - IFLScience - October 21st, 2019
- Healthcare Terms Are Out of Touch, Says Mom Advocate - Medscape - October 21st, 2019
- A stop-motion movie of the whole brain, starring new neurons - Spectrum - October 21st, 2019
- Humans evolved to think faster by slowing down brain development - New Scientist News - October 21st, 2019
- Stem Cell Banking Market was valued at $1986 million in 2016 - Markets Gazette - October 19th, 2019
- Republicans demand answers about government experiments with animals and fetal tissue - Washington Examiner - October 17th, 2019
- The Other Side of Stem Cell Research - The Tablet Catholic Newspaper - October 17th, 2019
- Reviewing MediciNova Inc. (MNOV)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly - October 17th, 2019
- SI-BONE Inc. (SIBN) and Cesca Therapeutics Inc. (NASDAQ:KOOL) Comparing side by side - MS Wkly - October 17th, 2019
- Inherited Learning? It Happens, but How Is Uncertain - Quanta Magazine - October 17th, 2019
- Contrasting of Brainstorm Cell Therapeutics Inc. (BCLI) and Magenta Therapeutics Inc. (NASDAQ:MGTA) - MS Wkly - October 17th, 2019
- Stem Cells Market to Gain Huge Traction Owing to Arrival of New-Fangled Treatments for Long-Lasting Sicknesses Till 2025 | Million Insights - P&T... - October 7th, 2019
- New Tools in the Works to Probe Adult Human Neurogenesis - The Scientist - October 7th, 2019
- Follow the lead of Aston Villa players and become a blood stem cell donor - 7500 To Holte - October 7th, 2019
- Starving Cancer by Cutting Off Its Favorite Foods, Glucose and Glutamine - American Council on Science and Health - October 6th, 2019
- We're making tiny brains in the lab should we be worried for them? - CBC.ca - October 6th, 2019
- Female Scientist To Lead Advanced Cancer Research Project In Space - SheThePeople - October 6th, 2019
- Cancer cells to be tested in zero gravity on Chinese Space Station - E&T Magazine - October 4th, 2019
- Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at 27th Annual Meeting of the European Orthopaedic... - October 4th, 2019
- Global Stem Cell Therapy Market Report, 2019-2030 : Focus on Treatment Type, Cell Source, Indication and Competitive Landscape - Space Market Research - October 4th, 2019
- Genmab Announces U.S. FDA Approval of DARZALEX (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple... - September 27th, 2019
- The unexpected functional diversity of reactive astrocytes - Baylor College of Medicine News - September 27th, 2019
- Troy resident 'gets it done' with ground-breaking treatment - Troy Daily News - September 27th, 2019
- Stem Cell Assay Market Overview by Industry Chain Information, Upstream Raw Materials & Downstream Industry 2017 2025 - Herald Space - September 27th, 2019